003850.KS
Boryung Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 8,900.00
+0.45%Year over year
Reported trailing growth
- Revenue
- +4.0%
- EBITDA
- +25.9%
- EBIT
- +3.5%
- EPS
- +245.5%
- Free cash flow
- +160.2%
- Operating cash flow
- +102.4%
Forward estimates
Based on analyst estimates
- Revenue
- -48.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- +0.9%
- EBIT
- +4.8%
- Net income
- +15.4%
- EPS
- +6.4%
- Free cash flow
- +143.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026